

**POLICY RELATED TO
POLITICAL AND LOBBYING
EXPENDITURES**

Effective March 14, 2021

DaVita Inc. (the “Company”) engages in legislative and administrative processes to support issues of importance to our business by taking action to ensure federal and state officials understand the needs of our patients and the mission of our Company. Our public policy priorities and advocacy efforts, including related trade association activities and political expenditures, are focused on advancing the interests of the Company, align with the public policy goals of the Company, and are made without regard for the personal political preferences of the Company’s executives, including the Company’s directors and officers. The Company’s political expenditures are made on a bipartisan basis to political parties, political committees and candidates that support issues that advance the interests of our patients, teammates and stockholders. DaVita’s longstanding policy has been that no gift or contribution will be given in anticipation of, in recognition of, or in return for an official act or anything that has the appearance of a gratuity, bribe, trade or quid pro quo of any kind.

The Company has established written internal policies and procedures regarding our corporate political giving, advocacy and lobbying expenses and the operation of the Company’s political action committee (“DaPAC”). Our expenses for advocacy include corporate expenses related to federal and state regulatory and legislative efforts, including policy development, lobbying, and advocacy related to state ballot initiatives or referendums. Our political spending includes corporate political contributions to state candidates for office and political donations to federal candidates from DaPAC. Certain members of the Company’s executive management team, including the Head of the Government Affairs team, as well as management members of our Government Affairs team, are involved in developing the annual funding goals for corporate advocacy efforts and political spending. The annual budget for all corporate political expenditures is reviewed and approved by the authorized corporate officers, which includes, at minimum, the Company’s Head of Government Affairs. Individual expenditures made within the confines of the authorized budget must be approved by the authorized member of the Government Affairs team. As part of that approval process, the Government Affairs team reviews the positions of the candidates or organizations to which contributions are proposed to determine whether those positions conflict the Company’s core values and policies (the “Policy Determinations”). With respect to DaPAC, the DaPAC executive chair, executive committee, some of whom are members of the Company’s senior management team, along with the Company’s senior management team, review and provide their concurrence with the DaPAC annual funding goals and related budget for DaPAC expenditures.

Board Oversight

The Company’s majority independent Board of Directors (the “Board”) oversees and supervises this policy (the “Policy”), as well as the Company’s public policy priorities and advocacy efforts, including lobbying expenditures or activities and political spending, which are conducted solely for promoting the long-term commercial, environmental, social and governance interests of the Company and/or promoting the interests of our patients and the Company. The Board receives reports, no less than annually, from senior management on these matters including a summary of (1) Policy Determinations that have occurred during the year, and (2) all lobbying and political spending, including payments to trade associations. The Board also receives information relating to the public policy and legislative priorities of the state and federal Government Affairs teams, status of legislation of interest to us, and updates on lobbying and political spending by the Company and DaPAC. Independent of the Policy Determinations report, the Board shall consider the broader societal and economic implications of the Company’s political spending.

In connection with its oversight of this Policy and the Company's public policy priorities and advocacy efforts, the Board shall oversee the Company's assessment of any potential risks related to the Company's political spending. Any material breaches of this Policy that are identified by or reported to the Government Affairs team or senior management shall be reported to the Board as soon as practicable.

Lobbying Activities

The Company's lobbying activities in the United States are strictly regulated by federal, state and local lobbying laws. We are committed to complying with the letter and spirit of each of the applicable laws. We file publicly available lobbying disclosure forms on a regular basis, as required by law, for spending by our Company, as described further below.

Federal Lobbying Activities

Federal lobbying activities are governed by the Lobbying Disclosure Act of 1995, as amended ("LDA"), which requires that organizations that employ federal lobbyists (within the meaning of the LDA), file a registration statement and quarterly lobbying activity reports disclosing corporate expenditures relating to lobbying and issues lobbied. The Company and its registered federal lobbyists are also required to file semi-annual disclosure reports detailing certain political contributions, and other specified payments relating to "covered officials" as defined within the LDA. These Company reports include contributions made by DaPAC.

The Company files federal lobbying reports with the Office of the Clerk of the U.S. House of Representatives and the Secretary of the U.S. Senate. These reports are publicly available at <http://lobbyingdisclosure.house.gov/>. The Company is also required to observe Federal laws that regulate the relationships between the Company and public officials to avoid conflicts of interest and to limit or prohibit certain gifts to public officials.

State Lobbying Activities

The state laws governing lobbying activity and related disclosures vary from state to state, but nearly all states require lobbyists, and those that hire lobbyists, to submit periodic disclosures reporting related spending. These reports generally include disclosures relating to lobbying expenditures, the legislative or regulatory issues that are the subject of lobbying, and the identity of the officials who benefit from any expenditures by the Company or its lobbyists. The Company is also required to observe state laws that regulate the relationships between the Company and public officials to avoid conflicts of interest and to limit or prohibit certain gifts to public officials.

The Company files state-level lobbying reports, and such reports generally are publicly available on the website of the state regulatory body that governs such disclosures.

DaVita Political Action Committee

As permitted by the federal election laws, the Company sponsors DaPAC, which makes contributions to federal candidates, political parties, and committees. Generally, DaPAC contributes to candidates who support and protect the legislative issues important to the Company, our teammates and/or our patients. Contributions by DaPAC are made without regard for the personal political preferences of the Company's executives, including the Company's directors and/or officers.

DaPAC is funded solely by voluntary contributions from eligible Company teammates. The Company does not pressure or coerce teammates to make personal political contributions to DaPAC or otherwise, nor take

any retaliatory action against teammates who do not. The Company does not reimburse teammates, directly or through compensation increases, for any personal political contributions or expenses, including contributions to DaPAC.

All DaPAC disbursements are publicly available on the Federal Election Commission's website at www.fec.gov.

Trade Associations

The Company participates in a very limited number of trade associations and membership organizations with which our Government Affairs team is involved. For example, the Company has memberships in two kidney care coalitions, Kidney Care Council and Kidney Care Partners, which engage on federal legislative and regulatory issues to advocate for patient access, quality care, and education programs, among other things. Members of our Government Affairs team serve on committees that set policies on legislative activities for these organizations. Additionally, the Company holds a seat on the board of each of these two organizations. The Government Affairs team is directly involved in other organizations in which it holds memberships, and in some cases, serves in leadership or policy making functions with those organizations. The Company includes in its reported Federal lobbying expenses (available at <http://lobbyingdisclosure.house.gov/>) the portion of our dues paid to these trade associations that is used for lobbying expenses.

Semi-Annual Report

Beginning no later than July 31, 2021, and semi-annually thereafter on or around January 31 and July 31, the Company will post this Policy and a report on <http://www.davita.com> that includes the following:

1. Links to the federal and state campaign finance disclosure forms filed by the Company (and other similar disclosure where links are not available), which disclose the amount contributed by the Company (or any entity owned or operated by the Company such as DaPAC) to political parties, candidates or other political committees;
2. For the top ten political contributions reported on the semi-annual report pursuant to item number 1 above (to candidates, political party committees, and political committees), an explanation of the reason for each contribution and the long-term policies of the Company supported by each contribution and the link, pursuant to item number 1 above, adjacent to the explanation;
3. Links to federal and state lobbying reports of the Company;
4. A list of the top five trade associations to whom DaVita paid funds in the preceding six-month period (either January 1 – June 30 or July 1 – December 31); and
5. A description of the Company's position on key policy priorities.